Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 265

1.

Defining the vulnerable period for re-establishment of Clostridium difficile colonization after treatment of C. difficile infection with oral vancomycin or metronidazole.

Abujamel T, Cadnum JL, Jury LA, Sunkesula VC, Kundrapu S, Jump RL, Stintzi AC, Donskey CJ.

PLoS One. 2013 Oct 2;8(10):e76269. doi: 10.1371/journal.pone.0076269. eCollection 2013.

2.

Comparison of clinical and microbiological response to treatment of Clostridium difficile-associated disease with metronidazole and vancomycin.

Al-Nassir WN, Sethi AK, Nerandzic MM, Bobulsky GS, Jump RL, Donskey CJ.

Clin Infect Dis. 2008 Jul 1;47(1):56-62. doi: 10.1086/588293.

PMID:
18491964
3.

Differences of the Fecal Microflora With Clostridium difficile Therapies.

Louie TJ, Byrne B, Emery J, Ward L, Krulicki W, Nguyen D, Wu K, Cannon K.

Clin Infect Dis. 2015 May 15;60 Suppl 2:S91-7. doi: 10.1093/cid/civ252.

PMID:
25922407
4.

A new strategy for the prevention of Clostridium difficile infection.

Howerton A, Patra M, Abel-Santos E.

J Infect Dis. 2013 May 15;207(10):1498-504. doi: 10.1093/infdis/jit068. Epub 2013 Feb 18.

PMID:
23420906
5.

Vancomycin and metronidazole for the treatment of Clostridium difficile-associated diarrhea.

Bishara J, Wattad M, Paul M.

Clin Infect Dis. 2007 Dec 15;45(12):1646-7; author reply 1649-51. doi: 10.1086/523720. No abstract available.

PMID:
18190329
6.

Vancomycin, metronidazole, or tolevamer for Clostridium difficile infection: results from two multinational, randomized, controlled trials.

Johnson S, Louie TJ, Gerding DN, Cornely OA, Chasan-Taber S, Fitts D, Gelone SP, Broom C, Davidson DM; Polymer Alternative for CDI Treatment (PACT) investigators.

Clin Infect Dis. 2014 Aug 1;59(3):345-54. doi: 10.1093/cid/ciu313. Epub 2014 May 5.

PMID:
24799326
7.

Treatment of asymptomatic Clostridium difficile carriers (fecal excretors) with vancomycin or metronidazole. A randomized, placebo-controlled trial.

Johnson S, Homann SR, Bettin KM, Quick JN, Clabots CR, Peterson LR, Gerding DN.

Ann Intern Med. 1992 Aug 15;117(4):297-302.

PMID:
1322075
8.

Vancomycin therapy for severe Clostridium difficile-associated diarrhea.

Huggan PJ, Murdoch DR.

Clin Infect Dis. 2007 Dec 15;45(12):1647-8; author reply 1649-51. doi: 10.1086/523719. No abstract available.

PMID:
18190330
9.

Persistence of skin contamination and environmental shedding of Clostridium difficile during and after treatment of C. difficile infection.

Sethi AK, Al-Nassir WN, Nerandzic MM, Bobulsky GS, Donskey CJ.

Infect Control Hosp Epidemiol. 2010 Jan;31(1):21-7. doi: 10.1086/649016.

PMID:
19929371
10.

Comparative Effectiveness of Vancomycin and Metronidazole for the Prevention of Recurrence and Death in Patients With Clostridium difficile Infection.

Stevens VW, Nelson RE, Schwab-Daugherty EM, Khader K, Jones MM, Brown KA, Greene T, Croft LD, Neuhauser M, Glassman P, Goetz MB, Samore MH, Rubin MA.

JAMA Intern Med. 2017 Apr 1;177(4):546-553. doi: 10.1001/jamainternmed.2016.9045.

PMID:
28166328
11.

Reduction in Clostridium difficile environmental contamination by hospitalized patients treated with fidaxomicin.

Biswas JS, Patel A, Otter JA, Wade P, Newsholme W, van Kleef E, Goldenberg SD.

J Hosp Infect. 2015 Jul;90(3):267-70. doi: 10.1016/j.jhin.2015.01.015. Epub 2015 Feb 9.

12.

Diagnosis and management of Clostridium difficile infection.

Dupont HL.

Clin Gastroenterol Hepatol. 2013 Oct;11(10):1216-23; quiz e73. doi: 10.1016/j.cgh.2013.03.016. Epub 2013 Mar 28. Review.

PMID:
23542332
13.

Lack of association of outcomes with treatment duration and microbiologic susceptibility data in Clostridium difficile infections in a non-NAP1/BI/027 setting.

Venugopal AA, Riederer K, Patel SM, Szpunar S, Jahamy H, Valenti S, Shemes SP, Khatib R, Johnson LB.

Scand J Infect Dis. 2012 Apr;44(4):243-9. doi: 10.3109/00365548.2011.631029. Epub 2011 Nov 13.

PMID:
22077148
14.

The role of vancomycin and metronidazole for the treatment of Clostridium difficile-associated diarrhea.

Tart SB.

J Pharm Pract. 2013 Oct;26(5):488-90. doi: 10.1177/0897190013499525. Epub 2013 Aug 12.

PMID:
23940121
15.

Clostridium difficile infection in older adults: a review and update on its management.

Kee VR.

Am J Geriatr Pharmacother. 2012 Feb;10(1):14-24. doi: 10.1016/j.amjopharm.2011.12.004. Epub 2012 Jan 20. Review.

PMID:
22260856
16.

Clostridium difficile-associated disease treatment response depends on definition of cure.

Lawrence SJ, Dubberke ER, Johnson S, Gerding DN.

Clin Infect Dis. 2007 Dec 15;45(12):1648; author reply 1649-51. doi: 10.1086/523718. No abstract available.

PMID:
18190331
17.
18.

Oral teicoplanin for successful treatment of severe refractory Clostridium difficile infection.

Popovic N, Korac M, Nesic Z, Milosevic B, Urosevic A, Jevtovic D, Pelemis M, Delic D, Prostran M, Milosevic I.

J Infect Dev Ctries. 2015 Oct 29;9(10):1062-7. doi: 10.3855/jidc.6335.

19.

Vancomycin treatment's association with delayed intestinal tissue injury, clostridial overgrowth, and recurrence of Clostridium difficile infection in mice.

Warren CA, van Opstal EJ, Riggins MS, Li Y, Moore JH, Kolling GL, Guerrant RL, Hoffman PS.

Antimicrob Agents Chemother. 2013 Feb;57(2):689-96. doi: 10.1128/AAC.00877-12. Epub 2012 Nov 12.

20.

Effect of metronidazole use on tacrolimus concentrations in transplant patients treated for Clostridium difficile.

Early CR, Park JM, Dorsch MP, Pogue KT, Hanigan SM.

Transpl Infect Dis. 2016 Oct;18(5):714-720. doi: 10.1111/tid.12588. Epub 2016 Sep 23.

Supplemental Content

Support Center